ACVR2A (LAE-102 Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA001260MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
LAE 102 research-grade biosimilar; LAE-102 research-grade biosimilar ;ACVR2A antibody; ACVR2 antibody; Activin receptor type-2A antibody; EC 2.7.11.30 antibody; Activin receptor type IIA antibody; ACTR-IIA antibody; ACTRIIA antibody
Species Reactivity
Human
Immunogen
Recombinant Human ACVR2A protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is designed as a research-grade biosimilar to LAE-102, targeting ACVR2A (Activin Receptor Type 2A), a transmembrane serine/threonine kinase receptor that plays a critical role in TGF-β superfamily signaling. ACVR2A mediates cellular responses to activins, myostatin, and related ligands, regulating diverse biological processes including muscle growth, bone metabolism, and cellular differentiation. Dysregulation of ACVR2A signaling has been implicated in multiple pathological conditions, including muscle wasting disorders, fibrodysplasia ossificans progressiva, and certain cancers where aberrant activin signaling contributes to tumor progression and metastasis.

LAE-102 has been utilized in research investigating ACVR2A-mediated signaling pathways and their therapeutic potential in muscle disorders and metabolic diseases. This biosimilar antibody provides researchers with a reliable tool for exploring ACVR2A function in various experimental contexts, including studies of receptor localization, protein-protein interactions, and pathway modulation. It supports investigations into the therapeutic targeting of activin-myostatin signaling for conditions involving muscle atrophy, metabolic dysfunction, and bone homeostasis.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin A, activin B and inhibin A. Mediates induction of adipogenesis by GDF6.
Gene References into Functions
  1. Altered decidual ACVR2A expression impairs the ability of stromal cells to properly decidualise and regulate trophoblast function at the maternalfetal interface, which may result in abnormal placentation that can lead to poor pregnancy outcomes such as pre-eclampsia. PMID: 29203340
  2. Results showed no association between genotypes and preeclampsia for polymorphisms rs5186, rs4606 in 3'UTR of genes ACVR2A, AGTR1 and RGS2 in women with preeclampsia PMID: 29593124
  3. TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence.( PMID: 27696331
  4. This locus harbors an evolutionary conserved gene-desert region with non-coding intergenic sequences likely involved in regulation of protein-coding flanking genes ZEB2 and ACVR2A. This region is intensively studied for mutations causing severe developmental/genetic disorders. Our analyses indicate a promising target region for interventions aimed to reduce risks of many major human diseases and mortality. PMID: 27832070
  5. Data suggest ALK1 and ACVR2A/ACVR2B, acting as BMP9 co-receptors, rearrange pro-domains of BMP9--pro-domain dimer complex leading to displacement of pro-domains after receptor binding, release of mature non-dimer BPM9, and activation of signaling. PMID: 26677222
  6. Activin A inhibited signaling by BMP-6 and BMP-9 by competing for type 2 receptors ACVR2A and ACVR2B. PMID: 26047946
  7. Data suggest that an SNP in promoter region of ACVR2A (rs1424954, the pre-eclampsia susceptibility allele) down-regulates 1) expression of ACVR2A in trophoblasts and 2) signal transduction in response to excess activin-A (as seen in pre-eclampsia). PMID: 25659497
  8. Adenomyotic tissues express high levels of myostatin, follistatin, and activin type II receptors. PMID: 26086422
  9. The gene ACVR2A was associated with the more severe early onset preeclampsia. PMID: 25499008
  10. For ACVR2A SNPs (rs10497025, rs1128919, rs13430086), no statistically significant difference was found between preeclampsia and control groups in terms of genotype and allele frequencies. PMID: 23633461
  11. ACVR2A was identified as a subnetwork component in functional association network analysis. PMID: 23263486
  12. ACVR2A showed statistically significant differential dose-expression relationship. PMID: 22848350
  13. ACVR2A interaction with Nodal and ADMP regulates head development from the 'organizer', a restricted group of cells in the embryo. PMID: 22949641
  14. This is the first report on the function of miR-195 in human placental trophoblast cells which reveals an invasion-promoting effect of the small RNA via repressing ActRIIA. PMID: 22723898
  15. Activin type IIA receptors are clearly demonstrable throughout the adult human hypothalamus and basal forebrain. PMID: 22296042
  16. Exonic selectivity for frameshift mutation within ACVR2 is specifically controlled by individual nucleotides flanking each coding ACVR2 microsatellite. PMID: 22001236
  17. Mutation in activin type II receptor is associated with colorectal cancer. PMID: 20197483
  18. crystal structure of BMP7 in complex with the extracellular domain (ECD) of the activin type II receptor PMID: 12667445
  19. Activin type II receptor gene (ACTRII) is probably involved in both non-microsattelite unstable and microsattelite-unstable colorectal carcinogenesis, but more frequently in the latter subgroup. PMID: 14691305
  20. Data indicate that activin A and activin receptors IIA and IIB may be involved in the regulation of germ cell proliferation in the human ovary during the period leading up to primordial follicle formation. PMID: 14738881
  21. Mutations highly frequent in microsatellite unstable(MSI-H) colon cancers and cause loss of ACVR2, indicating biallelic gene nactivation. Loss of activin signaling through mutation of ACVR2 may have role in genesis of MSI-H colorectal cancer. PMID: 14988818
  22. demonstrates that truncating mutations of the ACVR2 gene result in a significant reduction in activin mediated cell signaling. Inactivation of ACVR2 is a common event in prostate cancer and may play an important role in the development of prostate cancer PMID: 16337854
  23. structure of the ternary complex representing the signaling competent complex of BMP-2 bound to the entire extracellular domains of both its type I receptor, BMPR-Ia, & its type II receptor, ActRII, at a resolution of 2.2 angstroms PMID: 16672363
  24. Activin is growth suppressive and enhances migration in colon cancer. PMID: 17258738
  25. RGMa facilitates the use of ActRIIA by endogenous BMP2 and BMP4 ligands that otherwise prefer signaling via BMPRII and that increased utilization of ActRIIA leads to generation of an enhanced BMP signal PMID: 17472960
  26. Inhibin/activin BA subunit, follistatin, and activin receptor proteins and mRNAs are present in the human fetal palate. PMID: 18001154
  27. Populations with different ancestors (Iceland/Norway-Australia/New Zealand) demonstrate a common maternal pre-eclampsia susceptibility locus on chromosome 2q22-23, may suggests a general role of this locus, and possibly the ACVR2A gene, in pre-eclampsia. PMID: 18781190
  28. The -1 bp frameshift mutation rates of TGFBR2 and ACVR2 microsatellite sequences are dependent upon the human DNA Mismatch PMID: 18941508
  29. It remains unclear what role, if any, ACVR2A polymorphisms play in pre-eclampsia risk, at least in these Australian families. PMID: 19126782
  30. ActRII signaling is required for prostatic cancer cell and neuroblastoma cell viability, with ActRII mediating cell fate via the regulation of cell adhesion PMID: 19308291
  31. The four most frequently mutated genes in colorectal cancers with microsatellite instability were ACVR2 (92%), TAF1B (84%), ASTE1/HT001 (80%) and TGFBR2 (77%). PMID: 19503063

Show More

Hide All

Subcellular Location
Membrane; Single-pass type I membrane protein.
Protein Families
Protein kinase superfamily, TKL Ser/Thr protein kinase family, TGFB receptor subfamily
Database Links

HGNC: 173

OMIM: 102581

KEGG: hsa:92

STRING: 9606.ENSP00000241416

UniGene: Hs.470174

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*